Drugs / Group B Streptococcus Trivalent Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT01193920 | Oct 2010 → Dec 2011 | streptococcal infection | Novartis Vaccines | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT01446289 | Sep 2011 → Apr 2013 | streptococcal infection | Novartis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Group B Streptococcus Trivalent Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01193920 ↗ |
| Known as | GBS Trivalent Vaccine | “Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.” NCT01193920 ↗ |
| Modality | Vaccine | “This study will evaluate the safety and immunogenicity of a Group B Streptococcus vaccine at one dose in healthy non pregnant women and then in three different doses in healthy...” NCT01193920 ↗ |
| Route | Intramuscular | “Group B Streptococcus Trivalent Vaccine administered intramuscularly” NCT01446289 ↗ |